Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025OSLO, Norway, June 18, 2026 /PRNewswire/ — Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the…

Read the full release →

News provided by PR Newswire.